IP Library Granted Patent US 9,956,231
Granted Patent B1
US 9,956,231 · App. 15/843,590 · Granted May 1, 2018

Topical formulations comprising a steroid

Inventors: Udhumansha Ubaidulla (Namakkal, IN); Sateesh Kandavilli (Plainsboro, NJ); Ajay Sunil Vairale (Hyderabad, IN); Jeffrey A. Wayne (Markham, CA); Vijendra Nalamothu (Basking Ridge, NJ); Mistry Meghal (Ahmedabad, IN); Refika Isil Pakunlu (Highland Park, NJ)
Assignee: DR. REDDY'S LABORATORIES LTD.
A61K31/573A61K9/0014A61K31/58A61K47/10A61K47/14A61K47/36A61K47/38A61K47/44B05B1/02B05B1/30B05B11/3045B05B15/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,956,231
App. No.
15/843,590
Granted
May 1, 2018
Kind
B1
Abstract

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Claims (17)

1. A topical pharmaceutical composition comprising:

clobetasol;

an emulsifying agent from about 0.25% w/w to about 45% w/w of the composition;

a skin penetration enhancer from about 0.001% w/w to about 15% w/w of the composition;

a water-immiscible substance; and

water;

wherein the composition is non-foaming, propylene glycol-free, and propellant-free.

2. The composition according to claim 1 , wherein the clobetasol is clobetasol propionate.

3. The composition according to claim 1 , wherein the emulsifying agent comprises a cationic surfactant, anionic surfactant, zwitterionic surfactant, amphoteric surfactant, or any combination thereof.

4. The composition according to claim 3 , wherein the emulsifying agent is a sorbitan fatty acid ester, a mixture of partial esters of sorbitol and its mono- and di-anhydrides with fatty acids, a polyethylene glycol stearate, a glycol stearate, sodium lauryl sulphate, cetyl trialkyl ammonium bromide, a polyoxyethylene sorbitan fatty acid ester, glyceryl stearate, or any combination thereof.

5. The composition according to claim 1 , wherein the skin penetration enhancer comprises a polyol or ester thereof, an ether, a sulfoxide, a fatty acid, a fatty acid ester, or any combinations thereof.

6. The composition according to claim 5 , wherein the skin penetration is butanediol, polyethylene glycol monolaurate, diethylene glycol monoethyl ether, dimethylsulfoxide, decylmethylsulfoxide, lauric acid, oleic acid, valeric acid, isopropyl myristate, isopropyl palmitate, methyl propionate, ethyl oleate, or any combination thereof.

7. The composition according to claim 1 , wherein the water-immiscible comprises vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, or any combination thereof.

8. The composition of claim 1 further comprising an emollient comprising an oil of natural origin, a fatty acid or a monohydric alcohol ester thereof, a glycol, a branched aliphatic alcohol, or any combination thereof.

9. A method of treating a skin condition in a subject comprising

topically administering an effective amount of a composition according to claim 1 to the subject;

wherein the skin condition is one or more of atopic dermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reaction.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: ENCORE DERMATOLOGY, INC.
To: PRIMUS PHARMACEUTICALS, INC.
Reel/Frame 055576/0523 →
SECURITY INTEREST Recorded Nov 11, 2020
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: PENNRX VENTURES, LLC
Reel/Frame 054337/0330 →
SECURITY INTEREST Recorded Apr 22, 2019
From: ENCORE DERMATOLOGY, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 048958/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: PROMIUS PHARMA, LLC
To: ENCORE DERMATOLOGY, INC.
Reel/Frame 048941/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2018
From: DR. REDDY'S LABORATORIES LTD.
To: PROMIUS PHARMA LLC
Reel/Frame 045570/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2017
From: UBAIDULLA, UDHUMANSHA; NALAMOTHU, VIJENDRA; MEGHAL, MISTRY; VAIRALE, AJAY SUNIL; KANDAVILLI, SATEESH; WAYNE, JEFFREY A.; PAKUNLU, REFIKA ISIL
To: DR. REDDY'S LABORATORIES LTD.
Reel/Frame 044408/0330 →
Priority Claims (1)
IN 2111/CHE/2009 · Aug 31, 2009 · national
Continuity (7)
Continuation 15690851 · Aug 30, 2017
Continuation 15495148 · Apr 24, 2017
Continuation 15226684 · Aug 2, 2016
Continuation 15135259 · Apr 21, 2016
Continuation 15135298 · Apr 21, 2016
Continuation 13391972
Provisional Application 61256554 · Oct 30, 2009